Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JTE-061 cream in atopic dermatitis
jRCT2031210255Phase 3Completed
- Sponsor
- Japan Tobacco
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tapinarof in atopic dermatitis (AD) (3 arms), sponsored by Japan Tobacco. Primary endpoint: IGA treatment success at Week 8. Started Sep 2021; status: completed.
02
Drugs
tapinarof
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031210255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210255.